Topic

Understanding the risk of GA in nAMD

A look at research that sheds new light into the progression of geographic atrophy in neovascular age-related macular degeneration.

Also from the Angiogenesis, Exudation, and Degeneration meeting, emerging treatments for nAMD and MacTel2, and a marker for anti-VEGF success in ROP.

Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Three experts from Canada, Switzerland and Israel provide insights into the nuances of adherence, treatment intervals and emerging therapies.

An update on Port Delivery System with ranibizumab, a large-molecule anti-VEGF candidate and subretinal gene therapy to treat neovascular AMD.

Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.

How optical coherence tomography, OCT angiography and fluorescein angiography can help direct diagnosis and treatment decisions.

Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.

Emerging modalities and deep learning are helping to expose an old foe in non-neovascular age-related macular degeneration: reticular pseudodrusen.